Michael A Burgess Selected Research

antineoplaston A10 (A 10)

5/2007

We should desist using RECIST, at least in GIST.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael A Burgess Research Topics

Disease

6	Neoplasms (Cancer) 05/2007 - 09/2002
6	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 05/2007 - 12/2003
4	Sarcoma (Soft Tissue Sarcoma) 08/2004 - 09/2002
1	Hemangiosarcoma (Angiosarcoma) 05/2008
1	Necrosis 08/2004
1	Disease Progression 08/2003

Drug/Important Bio-Agent (IBA)

5	Imatinib Mesylate (Gleevec)FDA Link 05/2007 - 12/2003
4	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2004 - 09/2002
2	Ifosfamide FDA LinkGeneric 12/2003 - 09/2002
1	thiamine triphosphorate (TTP)IBA 05/2007
1	antineoplaston A10 (A 10)IBA 05/2007
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 05/2007
1	Phosphotransferases (Kinase)IBA 09/2004
1	Temozolomide (Temodar)FDA LinkGeneric 12/2003

Therapy/Procedure

3	Therapeutics 01/2007 - 09/2002
2	Neoadjuvant Therapy 05/2008 - 09/2002
1	Aftercare (After-Treatment) 01/2007
1	Drug Therapy (Chemotherapy) 12/2003
1	Adjuvant Chemotherapy 12/2003
1	Laparotomy 08/2003
1	Radiotherapy 08/2003